Kevin Whittlesey (2006 - 07 Congressional Fellow sponsored by Optical Society of America and Materials Research Society) has moved into
the gene therapy field at 4D Molecular Therapeutics as director of program and alliance management.
A virus that buoyed
the gene therapy field when it led to dramatic benefits in babies born with a fatal neuromuscular condition is under scrutiny.
For many years, our laboratory has been one of the global leaders in
the gene therapy field.
As a result, it could help revive
the gene therapy field, whose early clinical failures — including patient deaths — led some to dismiss it as overhyped.